-
公开(公告)号：US20120046242A1
公开(公告)日：2012-02-23
申请号：US13141838
申请日：2009-12-21
IPC分类号： A61K31/695 , A61K31/497 , A61K31/343 , A61K31/336 , A61K31/4402 , A61K31/015 , A61K31/553 , A61K31/55 , A61K31/4245 , A61K31/506 , A61K31/4406 , A61K31/167 , A61K31/4409 , A61K31/472 , A61K31/69 , A61K31/453 , A61K31/404 , A61K31/427 , A61K31/426 , A61P35/00 , A61K31/5377
CPC分类号： A61K31/708 , A61K31/015 , A61K31/047 , A61K31/15 , A61K31/166 , A61K31/167 , A61K31/196 , A61K31/201 , A61K31/24 , A61K31/27 , A61K31/336 , A61K31/35 , A61K31/351 , A61K31/352 , A61K31/353 , A61K31/357 , A61K31/365 , A61K31/366 , A61K31/403 , A61K31/404 , A61K31/405 , A61K31/407 , A61K31/4152 , A61K31/4178 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4439 , A61K31/472 , A61K31/495 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/5383 , A61K31/55 , A61K31/553 , A61K31/5575 , A61K31/565 , A61K31/57 , A61K31/585 , A61K31/69 , A61K31/695 , A61K31/7048
摘要： The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.
摘要翻译： 本发明涉及一种通过选择具有由异常Wnt / / bgr-连环蛋白信号传导的病症的受试者来治疗由异常Wnt / - 联合 - 连接蛋白信号传导的病症的受试者的方法，并向所选受试者施用化合物 选自由表1，表2中列出的那些及其药学上可接受的盐组成的组。 还讨论了在受试者中类似地调节Wnt / / bgr-连接蛋白途径的方法。
-
公开(公告)号：US20110251144A1
公开(公告)日：2011-10-13
申请号：US13119206
申请日：2009-09-16
IPC分类号： A61K31/7048 , A61K31/663 , A61K31/4406 , A61K31/167 , A61K31/203 , A61K31/424 , A61K31/553 , A61K31/428 , A61K31/52 , A61K31/444 , A61K31/197 , A61P35/00 , A61P19/08 , A61P3/10 , A61P7/00 , A61P25/00 , A61P25/28 , A61P17/14 , A61P1/02 , A61P31/18 , A61P35/02 , A61P25/24 , A61K31/495
CPC分类号： A61K31/428 , A61K31/167 , A61K31/198 , A61K31/203 , A61K31/365 , A61K31/4188 , A61K31/424 , A61K31/43 , A61K31/4406 , A61K31/444 , A61K31/495 , A61K31/52 , A61K31/553 , A61K31/663 , A61K31/7048
摘要： The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.
摘要翻译： 本发明涉及一种通过选择具有由异常Wnt / / bgr-连环蛋白信号传导的病症的受试者治疗由异常Wnt / / bgr- - 连环蛋白信号传导的病症的受试者的方法，并且至少对所选择的受试者施用 一种选自由表1，表2，表3所示的化合物及其药学上可接受的盐组成的组。 还讨论了在受试者中类似地调节Wnt / / bgr-连接蛋白途径的方法。
-
公开(公告)号：US20100015130A1
公开(公告)日：2010-01-21
申请号：US12474229
申请日：2009-05-28
申请人： Li-Huei Tsai , Yingwei Mao , Jon Madison , Stephen Haggarty
发明人： Li-Huei Tsai , Yingwei Mao , Jon Madison , Stephen Haggarty
IPC分类号： A61K39/395 , A61K38/00 , A61K31/496 , A61K31/445 , C07D409/14 , C07D211/08 , C07D207/14 , C07D405/14 , A61P29/00 , A61P37/00 , A61P25/00
CPC分类号： A61K38/1709 , A61K31/00 , A61K31/351 , A61K31/40
摘要： The invention relates to methods of treating neurological disorders in a subject, by activating a DISC1 pathway. Methods of promoting neurogenesis in adult neural progenitor cells, enhancing nerve generation and treating GSK3 disorders as well as related compositions are also provided.
摘要翻译： 本发明涉及通过激活DISC1途径治疗受试者神经障碍的方法。 还提供了促进成年神经祖细胞神经发生，增强神经产生和治疗GSK3疾病以及相关组合物的方法。
-
公开(公告)号：US20060239909A1
公开(公告)日：2006-10-26
申请号：US11386959
申请日：2006-03-22
申请人： Kenneth Anderson , James Bradner , Edward Greenberg , Teru Hideshima , Nicholas Kwiatkowski , Ralph Mazitschek , Stuart Schreiber , Jared Shaw , Stephen Haggarty
发明人： Kenneth Anderson , James Bradner , Edward Greenberg , Teru Hideshima , Nicholas Kwiatkowski , Ralph Mazitschek , Stuart Schreiber , Jared Shaw , Stephen Haggarty
IPC分类号： A61K51/00 , A61K39/395 , A61K33/36
CPC分类号： A61K38/05 , A61K31/35 , A61K31/357 , A61K31/422 , A61K31/4965 , A61K31/69 , A61K38/50 , A61K45/06 , A61K49/0008 , G01N33/5011 , A61K2300/00
摘要： The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
-
公开(公告)号：US20170049793A1
公开(公告)日：2017-02-23
申请号：US14701936
申请日：2015-05-01
IPC分类号： A61K31/708 , A61K31/353 , A61K31/7048 , A61K31/357 , A61K31/506 , A61K31/4406 , A61K31/167 , A61K31/196 , A61K31/24 , A61K31/4409 , A61K31/472 , A61K31/5377 , A61K31/69 , A61K31/15 , A61K31/495 , A61K31/426 , A61K31/52 , A61K31/404 , A61K31/405 , A61K31/4178 , A61K31/4439 , A61K31/047 , A61K31/695 , A61K31/407 , A61K31/403 , A61K31/421 , A61K31/5383 , A61K31/351 , A61K31/4152 , A61K31/166 , A61K31/585 , A61K31/57 , A61K31/565 , A61K31/365 , A61K31/201 , A61K31/336 , A61K31/4402 , A61K31/015 , A61K31/366 , A61K31/553 , A61K31/5575 , A61K31/55 , A61K31/27 , A61K31/4245 , A61K31/352
CPC分类号： A61K31/708 , A61K31/015 , A61K31/047 , A61K31/15 , A61K31/166 , A61K31/167 , A61K31/196 , A61K31/201 , A61K31/24 , A61K31/27 , A61K31/336 , A61K31/35 , A61K31/351 , A61K31/352 , A61K31/353 , A61K31/357 , A61K31/365 , A61K31/366 , A61K31/403 , A61K31/404 , A61K31/405 , A61K31/407 , A61K31/4152 , A61K31/4178 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4439 , A61K31/472 , A61K31/495 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/5383 , A61K31/55 , A61K31/553 , A61K31/5575 , A61K31/565 , A61K31/57 , A61K31/585 , A61K31/69 , A61K31/695 , A61K31/7048
摘要： The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.
摘要翻译： 本发明涉及通过选择具有由异常Wnt /β-连环蛋白信号传导介导的病症的受试者来治疗由异常Wnt /β-连环蛋白信号传导的病症的受试者的方法，并向所选择的受试者施用选自 由表1，表2所示的组及其药学上可接受的盐组成的组。 还讨论了在受试者中类似地调节Wnt /β-连环蛋白途径的方法。
-
公开(公告)号：US20120040916A1
公开(公告)日：2012-02-16
申请号：US13141442
申请日：2009-12-21
IPC分类号： A61K38/12 , A61K31/695 , A61K31/12 , A61P43/00 , A61K31/122 , A61K31/517 , A61K31/7034 , A61K31/365 , A61K31/4375
CPC分类号： A61K31/135
摘要： The present invention is directed toward a method of treating a subject for a condition mediated by the Wnt/β-catenin pathway by selecting a subject with a condition mediated by the Wnt/β-catenin pathway and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly inhibiting the Wnt/β-catenin pathway in a subject is also disclosed.
摘要翻译： 本发明涉及一种通过选择具有由Wnt / bgr-连接蛋白途径介导的病症的受试者来治疗由Wnt /β-连环蛋白途径介导的病症的受试者的方法，并向所选受试者施用化合物 选自由表1，表2中列出的那些及其药学上可接受的盐组成的组。 还公开了一种类似地抑制受试者中Wnt / bgr-catenin途径的方法。
-
7.发明申请EPIGENETIC MECHANISMS RE-ESTABLISH ACCESS TO LONG-TERM MEMORY AFTER NEURONAL LOSS 审中-公开神经机制在神经损失后重新获得长期记忆公开(公告)号：US20120039909A1
公开(公告)日：2012-02-16
申请号：US13279636
申请日：2011-10-24
IPC分类号： A61K31/167 , A61K31/404 , A61K31/166 , A61K31/353 , A61K48/00 , A61P25/00 , A61K39/395 , A61K31/7068 , A61K31/19 , A61K31/4406 , A61P25/28 , A61K31/4192 , A61K31/7088
CPC分类号： A61K31/164 , A61K31/19 , A61K31/215 , A61K31/404 , A61K31/4192 , A61K31/7052 , A61K31/7068
摘要： The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished through the increase of histone acetylation.
摘要翻译： 本发明涉及用于增强和改善丢失记忆恢复的方法和产品。 特别是通过增加组蛋白乙酰化来实现这些方法。
-
8.发明授权Epigenetic mechanisms re-establish access to long-term memory after neuronal loss 有权神经元损失后，表观遗传学机制重新获得长期记忆公开(公告)号：US08088951B2
公开(公告)日：2012-01-03
申请号：US11998834
申请日：2007-11-30
IPC分类号： C07C233/00
CPC分类号： A61K31/164 , A61K31/19 , A61K31/215 , A61K31/404 , A61K31/4192 , A61K31/7052 , A61K31/7068
摘要： The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished through the increase of histone acetylation.
摘要翻译： 本发明涉及用于增强和改善丢失记忆恢复的方法和产品。 特别是通过增加组蛋白乙酰化来实现这些方法。
-
9.发明申请COMPOSITIONS OF MODULATORS OF THE WNT/B-CATENIN PATHWAY AND AN N-CINNAMYL-N'BENZHYDRYL PIPERAZINE AND THEIR USE IN TREATING NEOPLASTIC CONDITIONS INCLUDING MALIGNANT MELANOMA 审中-公开WNT / B-CATENIN途径和N-CINNAMYL-N'BENZHYDRYL PIPERAZ的调节剂组合物及其在治疗恶性肿瘤细胞的神经病症中的应用公开(公告)号：US20110200686A1
公开(公告)日：2011-08-18
申请号：US12936695
申请日：2009-04-07
申请人： Randall T. Moon , Travis L. Biechele , Nathan D. Camp , Stephen Haggarty , Daniel Fass , Andy J. Chien
发明人： Randall T. Moon , Travis L. Biechele , Nathan D. Camp , Stephen Haggarty , Daniel Fass , Andy J. Chien
IPC分类号： A61K33/14 , A61K31/4965 , A61P35/00
CPC分类号： A61K33/00 , A61K31/496 , A61K33/14 , A61K45/06 , A61K2300/00
摘要： The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway or a pharmaceutically acceptable salt thereof and an N-cinnamyl-N′-benzhydryl piperazine or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating a neoplastic condition in a subject by administering the modulator of the Wnt/βcatenin pathway or a pharmaceutically acceptable salt thereof and an N-cinnamyl-N′-benzhydryl piperazine or a pharmaceutically acceptable salt thereof to the subject under conditions effective to treat a neoplastic disorder.
摘要翻译： 本发明涉及包含Wnt /β-连环蛋白途径的调节剂或其药学上可接受的盐和N-肉桂酰基-N'-二苯甲基哌嗪或其药学上可接受的盐的组合物。 本发明还涉及一种通过施用Wnt / / b-catenin途径的调节剂或其药学上可接受的盐和N-肉桂酰基-N'-二苯甲基哌嗪或其药学上可接受的盐来治疗受试者的肿瘤状况的方法 其盐在有效治疗肿瘤性疾病的条件下给予受试者。
-
10.发明申请COMPOSITIONS OF MODULATORS OF THE WNT/BETA-CATENIN PATHWAY AND BENZAMIDE AND/OR HYDROXAMIC ACID DERIVATIVES TO TREAT BIPOLAR DISORDER 审中-公开WNT / BETA-CTENIN路径和苯甲酰胺和/或羟基酸衍生物的调节剂组合物治疗双歧杆菌病公开(公告)号：US20130039998A1
公开(公告)日：2013-02-14
申请号：US13141747
申请日：2009-12-23
申请人： Daniel Fass , Stephen Haggarty , Edward Scolnick , Randall T. Moon , Travis L. Biechele , Nathan D. Camp
发明人： Daniel Fass , Stephen Haggarty , Edward Scolnick , Randall T. Moon , Travis L. Biechele , Nathan D. Camp
IPC分类号： A61K31/167 , A61K31/4406 , A61P25/00 , A61K31/513 , A61K33/14 , A61K33/00 , A61K31/4045 , A61K31/194
CPC分类号： C07D211/32
摘要： The present invention is directed to a composition comprising a modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/β-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject.
摘要翻译： 本发明涉及包含Wnt / / bgr-catenin途径的调节剂如GSK-3抑制剂或其药学上可接受的盐与苯甲酰胺衍生物或其药学上可接受的盐或与异羟肟酸 酸或其药学上可接受的盐。 本发明还涉及通过在有效治疗双相情感障碍的条件下向受试者施用苯甲酰胺衍生物或异羟肟酸来治疗受试者的双相性精神障碍的方法。 也可以向受试者施用Wnt / / bgr-catenin途径的调节剂，例如GSK-3抑制剂或其药学上可接受的盐。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.02 秒)
